Skip to content

US · QNRX · BIOTECHNOLOGY

Quoin Pharmaceuticals, Ltd. (QNRX) intrinsic value and stock valuation

$3.28as of 2026-11-21 · Mkt cap 9.62M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Quoin Pharmaceuticals, Ltd. DCF and intrinsic value

InvestorsCraft values QNRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QNRX’s statements →

Quoin Pharmaceuticals, Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ashburn, VA 20148-7349 quoinpharma.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-15.8M
20152025
Free cash flow
-$-13.54M
20152025
Total equity
$13.1M
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-16.29M-$-9.53M-$-9.38M-$-9.26M-$-6.06M
Net income-$-15.8M-$-8.96M-$-8.69M-$-9.38M-$-21.46M
EPSd-$-10.53M-$-68.92M-$-289.67M-$-23.45M—
Operating cash flow-$-13.54M-$-7.86M-$-7.86M-$-8.48M-$-5.72M
Capital expenditure$0.00$0.00$0.00-$-250K-$-620K
Free cash flow-$-13.54M-$-7.86M-$-7.86M-$-8.73M-$-6.35M
Total assets$20.4M$15.7M$12.2M$14.5M$9.36M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.82B-$-3.62M-$-2.4M-$-2.86M-$-7.48M
Total equity$13.1M$9.2M$5.66M$7.41M$660K
Cash and short-term investments$3.82B$14.1M$10.7M$12.9M$7.48M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$9.8M$3.6M$3.31M$2.67M$1.56M
Selling, general and administrative expenses$6.49M$5.93M$6.07M$6.58M$4.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$16.3M$9.53M$9.38M$9.26M$6.06M
Cost and expenses$16.3M$9.53M$9.38M$9.26M$6.06M
Interest income$480K$560K$690K$100K$0.00
Interest expense$0.00$0.00$0.00$710K$1.09M
Depreciation and amortization$100K$100K$100K$100K$100K
Ebitda-$-15.7M-$-8.86M-$-8.58M-$-8.56M-$-20.27M
Operating income-$-16.29M-$-9.53M-$-9.38M-$-9.26M-$-6.06M
Total other income/expenses, net$490K$570K$690K-$-120K-$-15.4M
Income before tax-$-15.8M-$-8.96M-$-8.69M-$-9.38M-$-21.46M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-15.8M-$-8.96M-$-8.69M-$-9.38M-$-21.46M
Weighted average shares outstanding$1.5M$130K$30K$400K$0.00
Weighted average diluted shares outstanding$1.5M$130K$30K$400K$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$3.82B$14.1M$10.7M$12.9M$7.48M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20M$14.9M$11.3M$13.4M$8.2M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$383.3M$480K$580K$700K$810K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$380K$780K$880K$1.09M$1.16M
Total assets$20.4M$15.7M$12.2M$14.5M$9.36M
Accounts payable$1.26M$910K$530K$610K$920K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.55M$4.18M$3.58M$3.53M$4.58M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.72M$2.32M$2.92M$3.52M$4.12M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$7.27M$6.5M$6.51M$7.05M$8.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-70.97M-$-55.17M-$-46.2M-$-37.52M-$-28.07M
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00$0.00$0.00
Total equity$13.1M$9.2M$5.66M$7.41M$660K
Total investments$14.9M$10.4M$8.29M$9.99M$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-3.82B-$-3.62M-$-2.4M-$-2.86M-$-7.48M
Cash flow statement
20252024202320222021
Net income-$-15.93M-$-9.01M-$-8.69M-$-9.38M-$-21.46M
Depreciation and amortization$100K$100K$100K$100K$100K
Stock-based compensation$1.15M$1.26M$1.09M$760K$0.00
Change in working capital$1.24M-$0.00$100K-$-90K$630K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.34M$280K$50K-$-220K$1.35M
Net cash provided by operating activities-$-13.54M-$-7.86M-$-7.86M-$-8.48M-$-5.72M
Investments in property, plant and equipment$0.00$0.00$0.00-$-250K-$-620K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-4.28M-$-1.89M$2.19M-$-10.15M-$-620K
Common stock issued$18.8M$11.6M$5.83M$14.8M$0.00
Common stock repurchased$0.00$0.00$0.00-$-14.82M$0.00
Dividends paid$0.00$0.00$0.00-$-65.27M$0.00
Net cash used for financing activities$18M$11M$5.22M$14M$13.5M
Net change in cash$190K$1.22M-$-460K-$-4.62M$7.16M
Cash at end of period$3.82M$3.62M$2.4M$2.86M$7.48M
Operating cash flow-$-13.54M-$-7.86M-$-7.86M-$-8.48M-$-5.72M
Capital expenditure$0.00$0.00$0.00-$-250K-$-620K
Free cash flow-$-13.54M-$-7.86M-$-7.86M-$-8.73M-$-6.35M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Quoin Pharmaceuticals, Ltd.

        Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

        CEO
        Michael Myers
        Employees
        4
        Beta
        1.66

        Explore

        Frequently asked questions

        What is the intrinsic value of Quoin Pharmaceuticals, Ltd. (QNRX)?

        InvestorsCraft does not currently publish an intrinsic value for QNRX. How the IC value is calculated.

        Is QNRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for QNRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.